Literature DB >> 16391870

GL15 and U251 glioblastoma-derived human cell lines are peculiarly susceptible to induction of mitotic death by very low concentrations of okadaic acid.

Emilia Castigli1, Miriam Sciaccaluga, Gianluca Schiavoni, Flora Brozzi, Roberto Fabiani, Paolo Gorello, Gian Luigi Gianfranceschi.   

Abstract

The challenging possibility of selectively inducing mitotic death in tumor cells by combining genotoxic agents with the inhibition of G2 checkpoints of the cell cycle is the subject of intensive investigation. We show that very low concentrations (3.5 and 5 nM) of okadaic acid induce mitotic death in two glioblastoma cell lines, in the absence of genotoxic agents. At the concentrations used, the main target of okadaic acid action is protein phosphatase 2A (PP2A), an enzyme deeply involved in the negative control of cell-cycle progression. The peculiar susceptibility of glioblastoma cells to induction of mitotic death by very low concentrations of okadaic acid must be related to an impairment of PP2A activity and to a specific deficiency in some cell-cycle checkpoints. In addition to its ability to induce abnormal mitoses in actively proliferating glioblastoma cells, okadaic acid possesses the ability to force semi-confluent glioblastoma cells to the M phase of the cell cycle, where they show the same abnormalities observed in actively proliferating glioblastoma cells. In semi-confluent cells the induction of mitotic death involves the activity of both the extracellular signal regulated kinases (ERKs) and the M-phase promoting factor: okadaic acid overstimulates ERK activity, and PD98059 (inhibitor of ERK activation) as well as roscovitine (S)-isomer (specific inhibitor of M-phase promoting factor activity) counteract the induction of mitotic death. Our results show that, without the use of genotoxic agents, it is possible to induce mitotic death in glioblastoma cells by activating the same uncontrolled pathways responsible for the uncontrolled proliferation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16391870

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  4 in total

1.  Mitochondrial dysfunction and effect of antiglycolytic bromopyruvic acid in GL15 glioblastoma cells.

Authors:  Lara Macchioni; Magdalena Davidescu; Miriam Sciaccaluga; Cristina Marchetti; Graziella Migliorati; Stefano Coaccioli; Rita Roberti; Lanfranco Corazzi; Emilia Castigli
Journal:  J Bioenerg Biomembr       Date:  2011-07-21       Impact factor: 2.945

2.  Bromopyruvate mediates autophagy and cardiolipin degradation to monolyso-cardiolipin in GL15 glioblastoma cells.

Authors:  Magdalena Davidescu; Miriam Sciaccaluga; Lara Macchioni; Roberto Angelini; Patrizia Lopalco; Maria Grazia Rambotti; Rita Roberti; Angela Corcelli; Emilia Castigli; Lanfranco Corazzi
Journal:  J Bioenerg Biomembr       Date:  2012-02-09       Impact factor: 2.945

3.  The energy blockers bromopyruvate and lonidamine lead GL15 glioblastoma cells to death by different p53-dependent routes.

Authors:  Magdalena Davidescu; Lara Macchioni; Gaetano Scaramozzino; Maria Cristina Marchetti; Graziella Migliorati; Rita Vitale; Angela Corcelli; Rita Roberti; Emilia Castigli; Lanfranco Corazzi
Journal:  Sci Rep       Date:  2015-09-21       Impact factor: 4.379

4.  M2 receptor activation inhibits cell cycle progression and survival in human glioblastoma cells.

Authors:  Michela Ferretti; Cinzia Fabbiano; Maria Di Bari; Claudia Conte; Emilia Castigli; Miriam Sciaccaluga; Donatella Ponti; Paola Ruggieri; Antonino Raco; Ruggero Ricordy; Antonella Calogero; Ada Maria Tata
Journal:  J Cell Mol Med       Date:  2013-03-14       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.